Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 61.64% is 35% below its 5-year average of 95.30%, around the middle of its 5-year range (-4.09%–100.00%).
18.52% below its 12-month average of 75.65%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
61.64%
GROSS MARGIN AVG TTM
75.65%
GROSS MARGIN AVG 3Y
100.00%
GROSS MARGIN AVG 5Y
95.30%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-18.52%
CURRENT VS 3Y AVG
-38.36%
CURRENT VS 5Y AVG
-35.32%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
43.48%
median of 568 covered companies
CURRENT VS SECTOR MEDIAN
+41.75%
vs the sector median at left
AbCellera Biologics Inc.
Market Cap
$4.16B
Gross Margin
61.64%
TTM Avg
75.65%
3Y Avg
100.00%
5Y Avg
95.30%
Market Cap
$4.30B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.33B
Gross Margin
80.08%
TTM Avg
75.94%
3Y Avg
72.82%
5Y Avg
72.82%
Market Cap
$4.41B
Gross Margin
83.86%
TTM Avg
80.36%
3Y Avg
82.01%
5Y Avg
82.83%
Market Cap
$4.56B
Gross Margin
75.44%
TTM Avg
66.98%
3Y Avg
64.58%
5Y Avg
67.25%
Market Cap
$4.67B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.68B
Gross Margin
33.56%
TTM Avg
32.27%
3Y Avg
30.18%
5Y Avg
31.09%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $4.16B | 61.64% | 75.65% | 100.00% | 95.30% |
| LivaNova PLC (LIVN)vs › | $4.16B | 68.18% | 68.59% | 68.31% | 67.52% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.30B | 0.00% | 0.00% | 0.00% | 0.00% |
| ICU Medical, Inc. (ICUI)vs › | $3.97B | 37.56% | 35.69% | 33.68% | 34.73% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.33B | 80.08% | 75.94% | 72.82% | 72.82% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.41B | 83.86% | 80.36% | 82.01% | 82.83% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.56B | 75.44% | 66.98% | 64.58% | 67.25% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.67B | 0.00% | 0.00% | 0.00% | 0.00% |
| LifeStance Health Group, Inc. (LFST)vs › | $4.68B | 33.56% | 32.27% | 30.18% | 31.09% |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.72B | 96.01% | 100.00% | 100.00% | 83.33% |
Gross Margin
61.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | -4.09% |
| 2025-12-31 | 82.34% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | 100.00% |
| 2023-06-30 | 100.00% |
| 2023-03-31 | 100.00% |
| 2022-12-31 | 92.79% |
| 2022-09-30 | 85.17% |
| 2022-06-30 | 88.65% |
| 2022-03-31 | 85.90% |
| 2021-12-31 | 84.29% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 86.94% |
| 2021-03-31 | 90.13% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 19.38% |
| 2019-06-30 | 18.88% |
| 2019-03-31 | 18.88% |
